Nuplazid: Novel Mechanism, Modest Benefits
The Carlat Psychiatry Report, Volume 18, Number 4, April 2020
Randall Moore, MD, JD.
Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences at Texas A & M University Health Science Center College of Medicine.
Chris Aiken, MD.
Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC.
Dr. Moore and Dr. Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Pimavanserin (Nuplazid) aims to treat psychosis without blocking dopamine. Though FDA-approved for psychosis associated with Parkinson’s disease, the drug is being tested in a host of other disorders: Depression, dementia, and sexual dysfunction.